Blockchain Registration Transaction Record

Regentis Biomaterials Targets $3B Cartilage Repair Market with Gelrin C

Regentis Biomaterials (RGNT) targets $3B cartilage repair market with Gelrin C hydrogel, a cell-free, single-procedure solution for knee osteoarthritis, potentially reducing the $5.7B-$15B annual U.S. economic burden.

This news matters because knee osteoarthritis affects millions, driving billions in healthcare costs and reducing quality of life. Gelrin C offers a single-procedure, cell-free solution that could make cartilage regeneration more accessible and affordable, potentially delaying or preventing the need for costly joint replacements. For patients, this means less invasive treatment and faster recovery, while healthcare systems could see reduced economic burden.